Low real-world early stent thrombosis rates in ST-elevation myocardial infarction patients and the use of bivalirudin, heparin alone or glycoprotein IIb/IIIa inhibitor treatment: A nationwide Swedish registry report-Reference-Cited by-同舟云学术

Low real-world early stent thrombosis rates in ST-elevation myocardial infarction patients and the use of bivalirudin, heparin alone or glycoprotein IIb/IIIa inhibitor treatment: A nationwide Swedish registry report

Published:2016-06 Issue: Volume:176 Page:78-82
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Grimfjärd Per,Erlinge David,Koul Sasha,Lagerqvist Bo,Svennblad Bodil,Varenhorst Christoph,James Stefan

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference15 articles.

1. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial;Mehran;Lancet,2009

2. Bivalirudin started during emergency transport for primary PCI;Steg;N Engl J Med,2013

3. Comparison of prasugrel and bivalirudin vs clopidogrel and heparin in patients with St-segment elevation myocardial infarction: design and rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial;Schulz;Clin Cardiol,2014

4. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial;Han,2015

5. Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome;Navarese;JACC Cardiovasc Interv,2015

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC);American Heart Journal;2018-04

2. Bivalirudin versus heparin and provisional GP IIb/IIIa inhibitors in patients treated for ST-segment elevation myocardial infarctions: Comparison of outcomes in a “real-world” setting;Journal of Interventional Cardiology;2017-06-07

3. Bivalirudin Across the Atlantic;JACC: Cardiovascular Interventions;2017-06

4. Effect of postprocedural full-dose infusion of bivalirudin on acute stent thrombosis in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Outcomes in a large real-world population;Cardiovascular Therapeutics;2017-05-12

5. How Long Does It Take for Clopidogrel and Ticagrelor to Inhibit Platelets in Patients Undergoing Primary Percutaneous Coronary Intervention? A Detailed Pharmacodynamic Analysis: Time Course of Platelet Reactivity in STEMI (TOPS);Seminars in Thrombosis and Hemostasis;2017-04-04